MX2022011400A - Aplicacion topica repetida de parche de capsaicina para usarse para tratar pacientes que no responden inicialmente al tratamiento. - Google Patents

Aplicacion topica repetida de parche de capsaicina para usarse para tratar pacientes que no responden inicialmente al tratamiento.

Info

Publication number
MX2022011400A
MX2022011400A MX2022011400A MX2022011400A MX2022011400A MX 2022011400 A MX2022011400 A MX 2022011400A MX 2022011400 A MX2022011400 A MX 2022011400A MX 2022011400 A MX2022011400 A MX 2022011400A MX 2022011400 A MX2022011400 A MX 2022011400A
Authority
MX
Mexico
Prior art keywords
capsaicinoid
responders
capsaicin
topical application
concentration capsaicin
Prior art date
Application number
MX2022011400A
Other languages
English (en)
Inventor
Marielle Eerdekens
Sylvia Engelen
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2022011400A publication Critical patent/MX2022011400A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención hace referencia al tratamiento repetido de una afección neuropática, preferentemente dolor neuropático periférico, mediante la aplicación de una o más unidades de dosis tópicas de capsaicinoide y/o capsaicinas de alta concentración, preferentemente parches de capsaicinoide y/o capsaicina de alta concentración, a pacientes que previamente no respondieron o respondieron de manera insuficiente a una aplicación previa de una o más unidades de dosis tópicas de capsaicinoide y/o capsaicinas de alta concentración, preferentemente parches de capsaicinoide y/o capsaicina de alta concentración o cualquier otra formulación de capsaicinoide y/o capsaicina de alta concentración administrada previamente en forma tópica.
MX2022011400A 2020-03-17 2021-03-17 Aplicacion topica repetida de parche de capsaicina para usarse para tratar pacientes que no responden inicialmente al tratamiento. MX2022011400A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20163651 2020-03-17
EP20167982 2020-04-03
EP20173133 2020-05-06
PCT/EP2021/056776 WO2021185887A1 (en) 2020-03-17 2021-03-17 Repeated topical application of capsaicin patch for treating initial non-responders

Publications (1)

Publication Number Publication Date
MX2022011400A true MX2022011400A (es) 2022-10-13

Family

ID=74871416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011400A MX2022011400A (es) 2020-03-17 2021-03-17 Aplicacion topica repetida de parche de capsaicina para usarse para tratar pacientes que no responden inicialmente al tratamiento.

Country Status (11)

Country Link
US (1) US20230157977A1 (es)
EP (1) EP4121027A1 (es)
JP (1) JP2023517745A (es)
KR (1) KR20220154160A (es)
CN (1) CN115297853A (es)
AU (1) AU2021238637A1 (es)
BR (1) BR112022018608A2 (es)
CA (1) CA3175582A1 (es)
CL (1) CL2022002538A1 (es)
MX (1) MX2022011400A (es)
WO (1) WO2021185887A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023178413A1 (en) * 2022-03-21 2023-09-28 360Medlink Inc. A method and a system for monitoring a treatment area of a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
JP2006513267A (ja) 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
PL219512B1 (pl) 2003-04-14 2015-05-29 Lohmann Therapie Syst Lts Plaster miejscowy, zastosowanie plastra miejscowego i sposób wytwarzania plastra miejscowego
ES2542847T3 (es) 2004-06-02 2015-08-12 Neurogesx Inc. Formulaciones que comprenden capsaicina, un anestésico local y/o un agente antipruriginoso para el tratamiento del dolor
EA013056B1 (ru) 2005-04-01 2010-02-26 Ньюроджесэкс, Инк. Масла капсаициноидов и способы их получения и применения
BR112014005358A8 (pt) 2011-09-09 2017-10-03 Propella Therapeutics Inc Composições compreendendo agonista seletivo de trpv1 e seus usos
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도

Also Published As

Publication number Publication date
KR20220154160A (ko) 2022-11-21
WO2021185887A1 (en) 2021-09-23
CA3175582A1 (en) 2021-09-23
EP4121027A1 (en) 2023-01-25
US20230157977A1 (en) 2023-05-25
CN115297853A (zh) 2022-11-04
CL2022002538A1 (es) 2023-04-21
BR112022018608A2 (pt) 2022-11-08
JP2023517745A (ja) 2023-04-26
AU2021238637A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
BRPI0510761A (pt) métodos de tratar um paciente afligido com pelo menos uma enfermidade e de reduzir ou eliminar rugas
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
BR0006024A (pt) Composição para o tratamento de inflamação e dor em mamìferos
MX2021008974A (es) Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof.
MX2022011400A (es) Aplicacion topica repetida de parche de capsaicina para usarse para tratar pacientes que no responden inicialmente al tratamiento.
AU2019210703B2 (en) Cannabinoid dosing regime for dermatitis and inflammatory skin conditions
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
Mishra et al. Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
AU2019211468B2 (en) Cannabinoid dosing regime for acne
MX2021003651A (es) Formulacion que comprende aceite ozonizado en el tratamiento de un tumor.
BR112022010733A2 (pt) Métodos para tratar dor
MX2022012219A (es) Regimen para la aplicacion topica repetida del parche de capsaicina.
MX2021016043A (es) Formulacion de doxorrubicina liposomal, metodo para producir una formulacion de doxorrubicina liposomal y uso de una formulacion de doxorrubicina liposomal como un medicamento.
MX2022006630A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso.
WO2022025785A8 (ru) Фармацевтическая композиция, включающая мемантин и цитиколин
MX2023005681A (es) Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol.
GB2624319A (en) Medical system using advanced analytics and machine learning
MX2022010593A (es) Composiciones tópicas de diclofenaco y métodos.
KR20220085086A (ko) 갑상선 기능 저하증을 동반한 대사 증후군을 치료하는 약제학적 복합제제